ClinicalTrials.gg
TerminatedNCT01111539Updated Oct 20, 2021Results posted

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

A Phase 3 interventional study of Escitalopram and Aripiprazole in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 62 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 8 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.

Enrollment
30th of 99
211 · median 80
Started
2010
with 8 others
Phase 3
18 of 100
1 open now
Registered
50th of 100
by date
Lead sponsor
5 of 100
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 30th largest by enrollment of the 99 interventional ones that give a count, is one of 9 that started in 2010, is one of 18 in phase 3, and was the 50th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing escitalopram in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.

Read the detailed description

The study will be organized as follows:

  • Screening Phase
  • Single-blind Prospective Treatment Phase
  • Single-blind Continuation Phase (Responder) or Double-blind Randomization Phase (non-Responder)
  • 30 day Post Treatment Follow-up

Assigned Interventions:

  • Escitalopram monotherapy
  • Aripiprazole/Escitalopram combination therapy
  • Aripiprazole monotherapy
03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major Depressive Disorder
  • MDD
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a current diagnosis of a major depressive episode. The current depressive episode must be ≥8 weeks in duration
  • Participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the and during the study period
  • Participants with a Hamilton Depression Rating Scale (HAM-D17) Total Score ≥18 at the Baseline Visit for the Prospective Treatment Phase

Exclusion criteria

Exclusion Criteria:

  • Lack of prior treatment with an antidepressant during the current depressive episode
  • Participants who report treatment with adjunctive or monotherapy antipsychotic treatment during the current depressive episode
  • Participants experiencing hallucinations, delusions or any psychotic symptomatology in the current depressive episode
  • Participants with epilepsy or significant history of seizure disorders
  • Participants with a current diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder
  • Participants who have received electroconvulsive therapy (ECT) in the last 10 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Phase B: Single-blind Prospective Treatment Phase

    Participants received initial dose of escitalopram 10 milligram (mg) blinded capsule (over-encapsulated tablet), orally, once daily, increased to 20 mg/day at the end of Week 1 based upon tolerability profile, for up to maximum of Week 8. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.

    Drug: Escitalopram · Drug: Blinded capsule

  • Experimental
    Phase B+: Single-blind Phase B Responders

    Participants with response (≥50% reduction in depressive symptom severity in Hamilton Depression Rating Scale {HAM-D17} Total Score; or a HAM-D17 Total Score of \<14 at Week 8 or a Clinical Global Impression of Improvement {CGI-I} Score of \<3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B, for up to maximum of Week 14, in Phase B+.

    Drug: Escitalopram · Drug: Blinded capsule

  • Experimental
    Phase C: Aripiprazole/Escitalopram Combination

    Participants with incomplete response (less than 50% reduction in depressive symptom severity between Baseline and Week 8 measured by the HAM-D17 Total Score and HAM-D17 Total Score of ≥14 at Week 8 and CGI-I Score of ≥3 at Week 6 and 8) at Week 8 received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily at Week 9. Participants were up titrated to aripiprazole target dose of 12 mg/day at Week 10 (if initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on initial 6 mg/day dose), and thereafter received same dose up to maximum of Week 14. No dose increases were allowed for aripiprazole after end of Week 12, however, doses might be decreased at any visit based upon tolerability. In combination with aripiprazole, participants received escitalopram (10 or 20 mg/day blinded capsules) taken during final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments allowed for escitalopram during Phase C.

    Drug: Escitalopram · Drug: Aripiprazole · Drug: Blinded capsule

  • Experimental
    Phase C: Escitalopram Monotherapy

    Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received escitalopram dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.

    Drug: Escitalopram · Drug: Blinded capsule

  • Experimental
    Phase C: Aripiprazole Monotherapy

    Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily for Week 9. Participants were up titrated to the aripiprazole target dose of 12 mg/day at Week 10 (if the initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on the initial 6 mg/day dose), and thereafter received the same dose for up to maximum of Week 14. No dose increases were allowed for aripiprazole after the end of Week 12, however, doses might be decreased at any visit based upon tolerability.

    Drug: Aripiprazole · Drug: Blinded capsule

Interventions

  • Escitalopram capsule administered orally, once daily without regard to meals.

  • Aripiprazole capsule administered orally, once daily without regard to meals.

  • DrugBlinded capsule

    Blinded capsule administered orally, once daily.

06

What researchers measure

Primary outcomes

  1. Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)

    The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change from Week 8 indicates improvement.

    Time frame: Week 8 to Week 14

Secondary outcomes

  1. Phase C: Mean Clinical Global Impression - Improvement (CGI-I) Scale Score at the End of Phase C (Week 14)

    CGI-I is a 7-point clinician-rated scale ranging from 1 to 7, rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A higher score indicates greater impairment.

    Time frame: Week 14

  2. Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)

    SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change from Week 8 indicates improvement.

    Time frame: Week 8 to Week 14

07

Results

Posted Oct 20, 2021
Limitations and caveats
The trial was terminated to allow support of additional programs in the central nervous system (CNS) therapeutic area where limited therapies are available and, thus, there exists heightened unmet medical need and is unrelated to any safety issues.

Participant flow

Participants took part in the study at 69 investigative sites in Estonia, Finland, Germany, India, Italy, Mexico, South Korea, Taiwan, Ukraine, and the United States from 13 July 2010 to 20 September 2011.

Phase B (Day 1 to Week 8)
Participant flow — Phase B (Day 1 to Week 8)
MilestonePhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Started2110000
Completed1290000
Not completed820000
Withdrew: Lost to follow-up60000
Withdrew: Adverse event50000
Withdrew: Sponsor discontinued study600000
Withdrew: Investigator withdrew subject10000
Withdrew: Subject withdrew consent70000
Withdrew: Protocol deviation20000
Withdrew: Lack of efficacy as determined by the investigator10000
Phase B+ and Phase C (Weeks 9 to 14)
Participant flow — Phase B+ and Phase C (Weeks 9 to 14)
MilestonePhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Started045282828
Intent-to-treat (itt) sample045282728
Safety sample045282728
Completed038222018
Not completed076810
Withdrew: Lost to follow-up00101
Withdrew: Adverse event00102
Withdrew: Sponsor discontinued study07455
Withdrew: Subject met withdrawal criteria00001
Withdrew: Investigator withdrew subject00010
Withdrew: Subject withdrew consent00020
Withdrew: Protocol deviation00001

Outcome measures

PrimaryPhase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)

The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change from Week 8 indicates improvement.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · score on a scale
Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)
score on a scalePhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)-8.0 ± 1.5-7.0 ± 1.5-4.3 ± 1.5
Statistical analysis
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Escitalopram Monotherapy · ANCOVA · p = =0.644 · Treatment difference: -1.0 · 95% CI -5.2 to 3.3
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Aripiprazole Monotherapy · ANCOVA · p = =0.080 · Treatment difference: -3.7 · 95% CI -7.8 to 0.4
SecondaryPhase C: Mean Clinical Global Impression - Improvement (CGI-I) Scale Score at the End of Phase C (Week 14)

CGI-I is a 7-point clinician-rated scale ranging from 1 to 7, rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A higher score indicates greater impairment.

Time frame:
Week 14
Reported as:
Mean · score on a scale
Phase C: Mean Clinical Global Impression - Improvement (CGI-I) Scale Score at the End of Phase C (Week 14)
score on a scalePhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Phase C: Mean Clinical Global Impression - Improvement (CGI-I) Scale Score at the End of Phase C (Week 14)2.6 ± 0.22.9 ± 0.23.0 ± 0.1
Statistical analysis
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Escitalopram Monotherapy · Cochran-Mantel-Haenszel · p = =0.366 · Treatment difference: -0.3 · 95% CI -0.8 to 0.3
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Aripiprazole Monotherapy · Cochran-Mantel-Haenszel · p = =0.138 · Treatment difference: -0.4 · 95% CI -0.9 to 0.1
SecondaryPhase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)

SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change from Week 8 indicates improvement.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · score on a scale
Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)
score on a scalePhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)-1.2 ± 0.4-1.2 ± 0.4-0.2 ± 0.4
Statistical analysis
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Escitalopram Monotherapy · ANCOVA · p = =0.995 · Treatment difference: -0.0 · 95% CI -1.2 to 1.2
  • Phase C: Aripiprazole/Escitalopram Combination vs Phase C: Aripiprazole Monotherapy · ANCOVA · p = =0.118 · Treatment difference: -0.9 · 95% CI -2.1 to 0.2

Adverse events

Collected over From first dose through 30 days after last dose of study drug (up to approximately 18 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase B: Single-blind Prospective Treatment Phase0/211 (0%)2/211 (0.9%)82/211 (38.9%)
Phase B+: Single-blind Phase B Responders0/45 (0%)0/45 (0%)3/45 (6.7%)
Phase C: Aripiprazole/Escitalopram Combination0/28 (0%)0/28 (0%)18/28 (64.3%)
Phase C: Escitalopram Monotherapy0/27 (0%)1/27 (3.7%)11/27 (40.7%)
Phase C: Aripiprazole Monotherapy0/28 (0%)1/28 (3.6%)17/28 (60.7%)
Most frequent serious events
Most frequent serious events
EventPhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
Cholecystitis acuteHepatobiliary disorders0/2110/450/281/270/28
SyncopeNervous system disorders0/2110/450/280/271/28
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2110/450/280/271/28
FallInjury, poisoning and procedural complications1/2110/450/280/270/28
Head injuryInjury, poisoning and procedural complications1/2110/450/280/270/28
Suicidal ideationPsychiatric disorders1/2110/450/280/270/28
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPhase B: Single-blind Prospective Treatment PhasePhase B+: Single-blind Phase B RespondersPhase C: Aripiprazole/Escitalopram CombinationPhase C: Escitalopram MonotherapyPhase C: Aripiprazole Monotherapy
AkathisiaNervous system disorders0/2110/452/281/275/28
HeadacheNervous system disorders36/2111/452/282/274/28
NauseaGastrointestinal disorders21/2110/451/282/274/28
SedationNervous system disorders3/2110/452/280/274/28
RestlessnessPsychiatric disorders1/2110/454/281/272/28
SomnolenceNervous system disorders12/2110/453/283/271/28
Seasonal allergyImmune system disorders2/2110/450/280/273/28
InsomniaPsychiatric disorders4/2110/453/282/271/28
DiarrhoeaGastrointestinal disorders12/2111/450/282/270/28
Increased appetiteMetabolism and nutrition disorders1/2110/450/282/271/28

Baseline characteristics

Phase B Sample included all participants who took at least one dose of escitalopram as indicated on the dosing record.

Age, Continuous
Age, Continuous(years)Phase B: Single-blind Prospective Treatment Phase
Mean44.4 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Phase B: Single-blind Prospective Treatment Phase
Female140
Male71
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase B: Single-blind Prospective Treatment Phase
Hispanic or Latino42
Not Hispanic or Latino168
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase B: Single-blind Prospective Treatment Phase
American Indian or Alaska Native16
Asian36
Native Hawaiian or Other Pacific Islander0
Black or African American23
White130
More than one race0
Unknown or Not Reported6
08

Study locations

62 sites
  • Cerritos, California 90703, United States
  • Costa Mesa, California 92626, United States
  • Irvine, California 92618, United States
  • San Diego, California 92102, United States
  • Santa Ana, California 92705, United States
  • Denver, Colorado 80204, United States
  • Cromwell, Connecticut 06416, United States
  • Hartford, Connecticut 06106, United States
  • Fort Walton Beach, Florida 32547, United States
  • Gainesville, Florida 32607, United States
  • Chicago, Illinois 60612, United States
  • Libertyville, Illinois 60048, United States
  • Boston, Massachusetts 02114, United States
  • Fall River, Massachusetts 02721, United States
  • Albuquerque, New Mexico 87109, United States
  • Bronx, New York 10467, United States
  • Fresh Meadows, New York 11366, United States
  • Staten Island, New York 10305, United States
  • Cary, North Carolina 27518, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Memphis, Tennessee 38119, United States
  • DeSoto, Texas 75115, United States
  • Richmond, Virginia 23230, United States
  • Brown Deer, Wisconsin 53223, United States
  • Jamejala, 71024, Estonia
  • Tallinn, 10617, Estonia
  • Tartu, 50406, Estonia
  • Tartu, 50407, Estonia
  • Helsinki, 00250, Finland
  • Helsinki, 00260, Finland
  • Kuopio, 70100, Finland
  • Oulu, 90100, Finland
  • Berlin, 10117, Germany
  • Berlin, 10969, Germany
  • Hamburg, 20246, Germany
  • Munich, 80336, Germany
  • Ostfildern, 73760, Germany
  • Study Site 1
    Ahmedabad, Gujarat 380006, India
  • Study Site 2
    Ahmedabad, Gujarat 380006, India
  • Mangalore, Karnataka 575001, India
  • Mumbai, Maharashtra 400026, India
  • Pune, Maharashtra 411030, India
  • Varanasi, Uttar Pradesh 221005, India
  • Catania, 95123, Italy
  • Siena, 53100, Italy
  • Gwangju, 501-75, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Seoul, 139-872, Korea, Republic of
  • Seoul, 150-713, Korea, Republic of
  • Seoul, 156-755, Korea, Republic of
  • Mexico, DF 06700, Mexico
  • Tlalnepantla de Baz, Estado Do Mexico 54050, Mexico
  • Zapopan, Jalisco 45200, Mexico
  • Monterrey, Nuevo Leon 64040, Mexico
  • Culiacan, Sinaloa 80020, Mexico
  • Villahermosa, Tabasco 86035, Mexico
  • Durango, 34000, Mexico
  • San Luis Potosi, 78218, Mexico
  • Changhua, 500, Taiwan
  • Kaohsiung, 802, Taiwan
  • Keelung, 204, Taiwan
  • Taoyuan, 333, Taiwan
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2010 to primary completion in Sep 2011, 14 months.

Results were first posted in Oct 2021, 10 years 1 month after primary completion. A results delay was requested in Aug 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2010
First posted
Apr 27, 2010
StartActual
Jul 13, 2010
Primary completionActual
Sep 20, 2011
CompletionActual
Sep 20, 2011
Results delay requested
Aug 17, 2012
Results first posted
Oct 20, 2021
Last update
Oct 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01111539
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
Jul 13, 2010
Primary completion
Sep 20, 2011
Completion
Sep 20, 2011
Results posted
Oct 20, 2021
Last update
Oct 20, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Escitalopram · Aripiprazole

Start the discussion